Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Public ClinicalTrials.gov record NCT04924075. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
Study identification
- NCT ID
- NCT04924075
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 322 participants
Conditions and interventions
Conditions
Interventions
- Belzutifan Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 11, 2021
- Primary completion
- Jun 3, 2029
- Completion
- Jun 3, 2029
- Last update posted
- May 3, 2026
2021 – 2029
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center ( Site 0110) | Los Angeles | California | 90048 | Recruiting |
| Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130) | Chicago | Illinois | 60611 | Recruiting |
| Northwestern Medicine Cancer Center - Warrenville ( Site 0134) | Warrenville | Illinois | 60555 | Recruiting |
| University of Iowa ( Site 0104) | Iowa City | Iowa | 52242 | Recruiting |
| Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108) | Baltimore | Maryland | 21287 | Recruiting |
| National Institutes of Health ( Site 0125) | Bethesda | Maryland | 20892 | Recruiting |
| Massachusetts General Hospital ( Site 0111) | Boston | Massachusetts | 02114 | Recruiting |
| University of Michigan ( Site 0126) | Ann Arbor | Michigan | 48109 | Recruiting |
| Washington University-Internal Medicine/Oncology ( Site 0124) | St Louis | Missouri | 63110 | Completed |
| Icahn School of Medicine at Mount Sinai ( Site 0123) | New York | New York | 10029 | Completed |
| Penn Medicine: University of Pennsylvania Health System-Heme/Onc ( Site 0127) | Philadelphia | Pennsylvania | 19104 | Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville | Tennessee | 37203 | Recruiting |
| Vanderbilt University Medical Center ( Site 0107) | Nashville | Tennessee | 37232 | Recruiting |
| University of Texas MD Anderson Cancer Center ( Site 0112) | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04924075, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04924075 live on ClinicalTrials.gov.